Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Infinity Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (148)	3/16/2007 4:44:18 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 210

Just skimming the report...a few snippets: This year hopefully we will see an oral 504 clinical trial announced. We should see selection of a hedgehog inhibitor candidate (I had expected it in March, I do not know if it has been delayed to later in the year...) The scientific advisory board disbanded in December 2006. They've listed Abbott, Gemin-X, and Ascenta Therapeutics, "among others, are each in early stage clinical development of small molecule drugs that target Bcl-2 and related family members" we have identified selective inhibitors of Bcl-2 and its related protein family member, Bcl-xL, and are performing lead optimization activities on these compounds.